4//SEC Filing
Session R.A. II 4
Accession 0001209191-21-068510
CIK 0001806310other
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 4:05 PM ET
Size
8.6 KB
Accession
0001209191-21-068510
Insider Transaction Report
Form 4
Session R.A. II
DirectorPresident and CEO10% Owner
Transactions
- Purchase
Common Stock
2021-11-23$12.12/sh+16,510$200,101→ 9,164,912 total - Purchase
Common Stock
2021-11-23$12.65/sh+26,008$329,001→ 9,190,920 total
Holdings
- 141,090(indirect: See footnote)
Common Stock
- 141,090(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.46 to $12.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2).
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.46 to $12.94 inclusive.
- [F3]The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I.
- [F4]The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001701846
Filing Metadata
- Form type
- 4
- Filed
- Dec 7, 7:00 PM ET
- Accepted
- Dec 8, 4:05 PM ET
- Size
- 8.6 KB